Evidence map›Paper›PMID 37464050›Full record

ArticleNPJ precision oncology2023

Grading of lung adenocarcinomas with simultaneous segmentation by artificial intelligence (GLASS-AI).

John H Lockhart, Hayley D Ackerman, Kyubum Lee, Mahmoud Abdalah, Andrew John Davis, Nicole Hackel, Theresa A Boyle, James Saller, Aysenur Keske, Kay Hänggi and 5 more

Open access · goldAbstract read
In one paragraph

Article in NPJ precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Artificial intelligence-enabled histological analysis in pre-clinical respiratory disease models: a scoping review.European respiratory review : an official journal of the European Respiratory Society · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

John H LockhartDepartments of Molecular Oncology, H. Lee Moffitt Cancer Center, Tampa, 33612, FL, USA.ORCID http://orcid.org/0000-0002-2727-6969
Hayley D AckermanDepartments of Molecular Oncology, H. Lee Moffitt Cancer Center, Tampa, 33612, FL, USA.ORCID http://orcid.org/0000-0002-1094-7949
Kyubum LeeBiostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, 33612, FL, USA.ORCID http://orcid.org/0000-0003-2015-3939
Mahmoud AbdalahQuantitative Imaging Core, H. Lee Moffitt Cancer Center, Tampa, 33612, FL, USA.
Andrew John DavisDepartments of Molecular Oncology, H. Lee Moffitt Cancer Center, Tampa, 33612, FL, USA.
Nicole HackelDepartments of Molecular Oncology, H. Lee Moffitt Cancer Center, Tampa, 33612, FL, USA.
Theresa A BoyleAnatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, 33612, FL, USA.
James SallerAnatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, 33612, FL, USA.
Aysenur KeskeImmunology, H. Lee Moffitt Cancer Center, Tampa, FL, 33612, USA.
Kay HänggiImmunology, H. Lee Moffitt Cancer Center, Tampa, FL, 33612, USA.
Brian RuffellImmunology, H. Lee Moffitt Cancer Center, Tampa, FL, 33612, USA.ORCID http://orcid.org/0000-0002-3846-6872
Olya StringfieldQuantitative Imaging Core, H. Lee Moffitt Cancer Center, Tampa, 33612, FL, USA.
W Douglas CressDepartments of Molecular Oncology, H. Lee Moffitt Cancer Center, Tampa, 33612, FL, USA.ORCID http://orcid.org/0000-0002-9119-3658
Aik Choon TanBiostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, 33612, FL, USA.
Elsa R FloresDepartments of Molecular Oncology, H. Lee Moffitt Cancer Center, Tampa, 33612, FL, USA. elsa.flores@moffitt.org.ORCID http://orcid.org/0000-0002-6173-2403
Moffitt Cancer Center · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Project 4P01CA250984 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RODRIGUEZ, PAULO CESAR · 2021 to 2025
$10.1M
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinomaR35CA197452 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FLORES, ELSA R · 2016 to 2022
$6.4M
Integrated Program in Cancer and Data Science (ICADS)T32CA233399 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI William Douglas Cress, Elsa R Flores · 2019 to 2026
$1.7M
NCI NIH HHS P01 CA250984NCI NIH HHS P30 CA076292NCI NIH HHS R35 CA197452NCI NIH HHS T32 CA233399
6 · The paper itself

Abstract

Preclinical genetically engineered mouse models (GEMMs) of lung adenocarcinoma are invaluable for investigating molecular drivers of tumor formation, progression, and therapeutic resistance. However, histological analysis of these GEMMs requires significant time and training to ensure accuracy and consistency. To achieve a more objective and standardized analysis, we used machine learning to create GLASS-AI, a histological image analysis tool that the broader cancer research community can utilize to grade, segment, and analyze tumors in preclinical models of lung adenocarcinoma. GLASS-AI demonstrates strong agreement with expert human raters while uncovering a significant degree of unreported intratumor heterogeneity. Integrating immunohistochemical staining with high-resolution grade analysis by GLASS-AI identified dysregulation of Mapk/Erk signaling in high-grade lung adenocarcinomas and locally advanced tumor regions. Our work demonstrates the benefit of employing GLASS-AI in preclinical lung adenocarcinoma models and the power of integrating machine learning and molecular biology techniques for studying the molecular pathways that underlie cancer progression.

Identifiers

PMID37464050
PMCPMC10354042
OpenAlexW4384662134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.